Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

PURPOSE: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab tesirine (Rova-T) is an antibody–drug conjugate targeting delta-like 3 protein (DLL3). This open-label, single-arm...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Morgensztern, Daniel, Besse, Benjamin, Greillier, Laurent, Santana-Davila, Rafael, Ready, Neal, Hann, Christine L., Glisson, Bonnie S., Farago, Anna F., Dowlati, Afshin, Rudin, Charles M., Le Moulec, Sylvestre, Lally, Satwant, Yalamanchili, Sreeni, Wolf, Jürgen, Govindan, Ramaswamy, Carbone, David P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7105795/
https://ncbi.nlm.nih.gov/pubmed/31506387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1133
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia